Tourette Syndrome

Tourette syndrome (TS) is a childhood-onset neurodevelopmental disorder characterized by multiple motor tics and one or more vocal tics.^[1] Once considered rare, it is now recognized to affect approximately 1% of the general population — meaning the average family practitioner with a caseload of 2,000 patients cares for roughly 20 people with TS, many of whom may never have been formally diagnosed as such.^[2] A population-based meta-analysis of 13 school-based studies found a prevalence of 7.7 per 1,000 children specifically for Tourette syndrome, with transient tic disorder considerably more common, at 29.9 per 1,000 children; boys are affected roughly 4 times as often as girls.^[3] Tics occur in all races and cultures.^[3]

Two facts should shape every clinical encounter with a patient who has TS. First, the natural history is genuinely reassuring: tics classically begin around age 6-7, tend to peak in severity around age 10-12, and then decline through adolescence and early adulthood in the majority of patients — nearly three-quarters of patients report their tics are greatly diminished by adulthood, and over a third become tic-free.^[3][4][1] Second, psychiatric comorbidity is the rule, not the exception, and is frequently the more impairing problem: in a multi-site international database of 3,500 individuals with tic disorders, only 12% had tics with no associated neuropsychiatric comorbidity at all, and ADHD or OCD is present in most patients.^[3][1] These two facts together mean that management is rarely just about the tics — it is about honest, reassuring prognostic counseling, and about identifying and treating whichever condition (tics, ADHD, OCD, anxiety) is actually driving the patient's impairment.

Diagnostic criteria (DSM-5)

• Both multiple motor tics and one or more vocal tics have been present at some time during the illness, although not necessarily concurrently.^[1][3]
• The tics may wax and wane in frequency but have persisted for more than 1 year since the first tic onset.^[1][3]
• Onset is before age 18 years.^[1][3]
• The disturbance is not attributable to the physiological effects of a substance (for example, stimulants or cocaine) or another medical condition (for example, Huntington's disease or postviral encephalitis).^[1][3]

Two related, genuinely testable diagnoses use the same core framework: persistent (chronic) motor or vocal tic disorder meets every criterion for TS except that only motor tics or only vocal tics have occurred, never both; and provisional tic disorder meets every criterion except that tics have not yet lasted longer than a year. There is no clear pathophysiological difference between these three; they are distinguished purely by tic type and duration.^[1]

What a tic actually looks like

A tic is a sudden, rapid, recurrent, nonrhythmic, stereotyped motor movement or vocalization.^[1] Simple motor tics are brief and meaningless — eye blinking, eye movements, grimacing, head jerks, or shoulder shrugs — and are typically the first tics to appear, usually starting with facial tics such as blinking. Complex motor tics are slower, longer, more purposeful-looking movements that are rarely seen without simple motor tics already present, and include touching objects or oneself, dystonic postures, or obscene gestures (copropraxia). Simple vocal tics are sudden, meaningless sounds — throat clearing, coughing, sniffing, barking, or grunting — and usually appear after motor tics do. Complex vocal tics include uttering syllables, words, phrases, or statements; echo phenomena; and, less commonly than popular depictions suggest, obscene or aggressive words or statements (coprolalia).^[3] Echophenomena (echolalia — repeating others' words — and echopraxia — repeating others' movements) occur in over half of children with TS, more often alongside comorbid OCD; coprolalia, by contrast, affects fewer than 10% of patients with TS and should not be treated as a defining or required feature.^[1]

The premonitory urge

Most children over age 10 describe a "premonitory urge" before a tic — a sensation or itch, or bodily discomfort, most often compared to the sensation preceding a sneeze, that builds until relieved by performing the tic.^[3][1] About 20% of patients describe a specifically sensory quality to this urge (itching, tingling, aching). Younger children report this urge far less consistently than older children or adults, for reasons that are not well understood, which is part of why habit-reversal-based behavioural therapy (which depends on urge awareness) tends to work less well in very young children.^[1]

A genuinely useful clinical pattern: masking at school, "purging" at home

Tics are involuntary in the sense that a patient cannot simply choose to stop them, but they are under a real degree of voluntary influence — most patients can suppress tics for a period of time, at the cost of a mounting, distressing urge and a real cognitive/attentional toll.^[1][3] A very common and clinically useful pattern follows from this: children frequently suppress tics all day at school, arriving home with a burst of very frequent tics, while their teacher reports no problem at all in the classroom. This is not evidence the tics are voluntary, fabricated, or under the child's full control — it is an adaptive coping strategy, and parents should be specifically reassured that home is meant to be the safe place where a child can release tics they have been holding in all day.^[1]

Waxing, waning, and situational triggers

Tics characteristically wax and wane, and manifest differently at different times and ages; different tics can persist for variable periods, often with several types overlapping.^[3][1] Stress, excitement, and fatigue commonly worsen tics; a longstanding clinical concern that voluntarily suppressing tics causes a later "rebound" worsening has been more recently debunked by newer evidence and should not be used to discourage suppression strategies used in behavioural therapy.^[5]

• Male sex — boys are affected roughly 3 to 4 times as often as girls.^[3][1]
• Family history — TS is one of the most heritable non-Mendelian neuropsychiatric disorders known: a family history is present in about 52% of cases, a first-degree relative carries roughly 10 times the general population's risk, and the concordance ratio in monozygotic twins is about 5:1 compared with dizygotic twins.^[1] Despite this strong heritability, TS is highly polygenic, and no single causal gene has been identified despite extensive study.^[1]
• A family history of ADHD, OCD, or anxiety disorder — these frequently cluster in the same families as TS and should specifically be asked about, since they raise the likelihood of comorbidity in the index patient as well.^[1]
• Suggested but less firmly established environmental contributors include perinatal injury, infection, and autoimmune mechanisms; none of these currently changes routine management for a typical presentation.^[1]
• Age itself is a "risk factor" for symptom severity in a specific sense: tic severity is expected to be highest in the childhood-to-early-adolescent years (typically peaking around age 10-12) and to decline through later adolescence and early adulthood in most patients — this expected trajectory, not a fixed severity threshold, is what should anchor counseling and treatment decisions.^[3][4]

Tourette syndrome is a clinical diagnosis

Diagnosis is based on a clinical interview and history, including a family history and, where possible, a collaborative history from school — it is not uncommon for tics to be actively suppressed during the physician interview itself, which can make the office examination misleadingly reassuring.^[3] There is no laboratory test or imaging study that confirms TS; the neurological examination should be normal apart from the tics themselves, and routine bloodwork, EEG, or brain imaging are not indicated for a typical presentation.^[3][1]

Screening and rating tools

The Yale Global Tic Severity Scale (YGTSS) is the gold-standard clinician-rated instrument used in most TS research and is practical to use in clinic.^[3][1] Self- and parent-report tools that can support (not replace) clinical assessment include the MOVES (Motor tic, Obsessions and compulsions, Vocal tic, Evaluation Survey), the Tourette Symptom Self Report, and the Parent Tic Questionnaire.^[3]

Comorbidity screening is not optional

Because only about 12% of patients in tertiary-care TS databases have tics with no other neuropsychiatric comorbidity, a careful, structured screen for the most common associated conditions should be part of every initial assessment and periodic reassessment: ADHD, executive dysfunction, OCD/obsessive-compulsive behaviours, mood dysregulation, other behaviour problems, learning disability, speech and language disorders, and sleep disorders.^[3] Community-based direct-interview studies found ADHD co-morbidity in 38% of children with tic disorders, and clinic-based studies report rates as high as 60% (with individual site ranges of 33-91%).^[3] Self-report tools (Child Behavior Checklist, Strengths and Difficulties Questionnaire) and structured interviews (K-SADS, Mini International Neuropsychiatric Interview) can support this screening.^[3]

Differential diagnosis

From a phenomenological standpoint, simple motor tics must be differentiated from myoclonus, chorea, seizures, dystonia, and muscle spasms/cramps; complex motor tics must be differentiated from motor stereotypies, restless leg syndrome, akathisia, and compulsions.^[3] Useful distinguishing features:

• Motor stereotypies — rare, rhythmic, repetitive, fixed, predictable, purposeless movements (arm flapping, hand flapping, head nodding, rocking) in an otherwise typically developing child; unlike TS, onset is typically before age 3, a single repetitive movement pattern (rather than multiple, evolving tics) predominates, movements are easier to voluntarily interrupt, occur mainly when the child is excited, and characteristically decrease as the child reaches elementary-school age.^[1]
• Chorea — jerky, involuntary, more constant (less waxing-and-waning) movements affecting especially the shoulders, hips, and face; far less common in childhood than tics.^[1]
• Paroxysmal dyskinesias — abnormal movements precipitated by a startle or sudden movement, usually brief (seconds to minutes), sometimes preceded by an unusual limb sensation; often associated with dystonia and sometimes chorea/ballism; usually autosomal dominant but can be sporadic.^[1]
• Akathisia — inner restlessness with an inability to stay still, most often a side effect of an antipsychotic, antidepressant, or antiemetic — a specifically pharmacist-relevant differential when a patient is already on one of these drug classes.^[1]
• Absence seizures with eyelid myoclonia — similar age range and, since blinking is often the first tic, can superficially resemble each other; seizures involve altered consciousness or staring and are not typically worsened by anxiety, unlike tics; routine EEG is not indicated for typical tics but should be considered if altered consciousness is a genuine concern.^[1]
• Obsessive-compulsive disorder — compulsions are performed specifically to relieve anxiety tied to an obsession, whereas tics are preceded by a premonitory urge rather than a specific feared consequence; genuine overlap and diagnostic difficulty is common, particularly given how frequently the two conditions co-occur in the same patient.^[1]
• Functional (psychogenic) tic-like behaviour — a genuine and increasingly recognized mimic, particularly in adolescent and young adult females with rapid (hours-to-days) onset of complex tic-like movements and vocalizations with no preceding history of simple childhood tics, often with atypical phenomenology and documented exposure to social media content depicting tics; a rise in these presentations was specifically linked to increased social media use during the COVID-19 pandemic.^[6] This distinction matters clinically: management centres on the underlying functional/psychiatric drivers rather than default TS pharmacotherapy.
• Secondary tic-like movements from another neurological condition — a structured secondary-cause table is genuinely useful: Huntington's disease (chorea, clonic/dystonic tics; confirm with DNA analysis), neuroacanthocytosis (mouth movements, lip biting, motor and phonic tics; acanthocytosis on blood smear, elevated creatine kinase), Wilson's disease (dystonia and dystonic tics; low ceruloplasmin, elevated urinary copper, Kayser-Fleischer rings), Sydenham's chorea (chorea, tic-like movements; group A beta-haemolytic strep serology), and drug-induced tics (motor and phonic tics from stimulant drug use, cocaine, or tardive tics secondary to antipsychotic exposure).^[3]

• There is no fixed frequency or severity of tics that automatically warrants treatment — treat when symptoms genuinely interfere with academic, vocational, or social functioning, or cause physical pain or psychological distress, not simply because tics are visible on examination.^[2]
• In most patients, providing an accurate diagnosis and clear information about etiology, natural history, and prognosis is itself sufficient management — this genuinely reassures many families and should not be skipped in favour of jumping straight to therapy.^[2]
• Screen for and prioritize comorbid ADHD, OCD, anxiety, and mood/behaviour problems at every assessment — these are frequently the actual driver of impairment and should be treated as such, not deferred while tics alone are addressed.^[3][1]
• Choose the least intrusive, effective intervention with the smallest risk of adverse effects first, and escalate only as genuinely needed — in practical terms this means behavioural therapy and alpha-2 agonists before antipsychotics or tetrabenazine.^[4]
• Set realistic expectations from the outset: medications suppress tics in the present and do not alter the underlying natural history of the disorder, which is expected to improve substantially through adolescence into adulthood for most patients regardless of treatment.^[4]
• Reserve highly invasive treatment (deep brain stimulation) for the most severe, medically refractory adult disease, and avoid it in patients younger than 20.^[2]
• For comorbid ADHD specifically: do not withhold appropriately dosed stimulant treatment for genuinely impairing ADHD symptoms out of an outdated, now evidence-updated fear of worsening tics (see Choose Initial Treatment).^[7]

Behavioural therapy — first-line for tics causing impairment

First-line, both children and adults Comprehensive Behavioral Intervention for Tics (CBIT), built around habit-reversal therapy (HRT): training the patient to recognize the premonitory urge, then perform a voluntary, physically incompatible "competing response" until the urge passes, often alongside relaxation training for anxiety and strategies addressing situational triggers.^[5][1] HRT carries a strong recommendation, high-quality evidence grade; a well-conducted pediatric RCT of CBIT specifically (126 youth, 8 sessions over 10 weeks) found YGTSS scores fell from 24.7 to 17.1 with CBIT versus 24.6 to 21.1 with supportive therapy/education (group difference at week 10, P<0.001), with 52.5% rated much or very much improved versus 18.5% on supportive therapy, and 86.9% of CBIT responders still responding at 6-month follow-up.^[5] Exposure and response prevention (ERP) — the same technique used for OCD, adapted for tics — carries a strong recommendation, low-quality evidence grade and is a reasonable alternative where a trained HRT/CBIT therapist is not locally available, since ERP-trained (OCD) therapists may be easier to find in some centres.^[5] Behavioural therapy is less likely to help children aged 9 or younger (who often cannot reliably identify the premonitory urge the technique depends on) or patients with severe, untreated ADHD that limits their ability to sustain engagement in therapy — treat or stabilize significant ADHD symptoms first, or in parallel, in these patients.^[5]

Pharmacotherapy for tics — when behavioural therapy is unavailable, insufficient, or tics are more severe

First-line pharmacotherapy for mild-moderate tics an alpha-2 agonist — clonidine or guanfacine — carries a strong recommendation, moderate-quality evidence grade for both, with a more favourable adverse-effect profile than antipsychotics, and is specifically favoured when ADHD is also present, since both agents have separately demonstrated benefit for ADHD symptoms as well as tics.^[4] Clonidine dosing should be titrated according to blood pressure and heart rate, is never stopped abruptly (risk of rebound hypertension), and a once-weekly transdermal patch formulation (1-2 mg) is also effective and useful when adherence to multiple daily oral doses is difficult.^[4] Guanfacine follows the same titrate-to-vitals principle. Second-line an atypical antipsychotic — risperidone (weak recommendation, but high-quality evidence for efficacy; requires monitoring for extrapyramidal and metabolic effects) or aripiprazole (weak recommendation, low-quality evidence; somewhat more favourable metabolic profile than risperidone or olanzapine, though still a real burden) — is reasonable when tics are more severe or alpha-2 agonists are inadequate or not tolerated.^[4] Third-line, or for coprolalia/severe vocal tics the older typical antipsychotics — pimozide and haloperidol — have the largest and highest-quality efficacy evidence base of any tic medication studied, which is precisely why they were historically first-line; they are placed third-line here because of their genuine, significant extrapyramidal, sedative, and (for pimozide) QTc-prolongation burden, and because newer agents achieve meaningful benefit with a better-tolerated side-effect profile.^[4] Topiramate is a reasonable alternative (weak recommendation, low-quality evidence) when first- and second-line agents are contraindicated, not tolerated, or inadequate.^[4]

Refractory or severely disabling focal tics

Severely disabling vocal tics (including coprolalia) or very distressing motor tics of the upper face or neck botulinum toxin injection by an experienced clinician only — a randomized trial found a median 39% reduction in tics with active injection versus a 5.8% increase with placebo, though with a genuine risk of injected-muscle weakness, transient dysphagia (with laryngeal injection), and, uncommonly, a new tic emerging to replace the treated one.^[4] Refractory to an adequate trial of the above tetrabenazine carries only a weak recommendation and very-low-quality evidence (based on a single small open-label study), with a real burden of extrapyramidal effects, depression, anxiety, and parkinsonism — death due to pneumonia has been described with its use, so reserve it for genuinely refractory disease and monitor closely.^[4] Deep brain stimulation is not recommended in children, and carries only a Category X1 (insufficient evidence for a formal recommendation) grade in adults; reserve it for the most severe, medically refractory tics in adults, and only within a research program run by physicians with specific DBS/tic-management expertise.^[2][5]

Comorbid ADHD — the point most likely to be gotten wrong

Do not withhold an appropriately dosed stimulant for genuinely impairing ADHD out of fear of worsening tics. For decades, clinicians were reluctant to treat ADHD with stimulants in patients with tics, based on case reports and small case series from the 1970s-80s describing tic onset or worsening after starting a stimulant.^[7] A systematic review of randomized, double-blind, placebo-controlled trials conducted specifically in children with co-morbid ADHD and tic disorders found that short-term use of stimulants at moderate doses has not been found to worsen tics on average, and both methylphenidate (strong recommendation, high-quality evidence) and dextroamphetamine (strong recommendation, low-quality evidence) are effective, evidence-supported ADHD treatments in this population.^[7] This does not mean tic worsening never happens in an individual patient — it can, and the risk appears greater at higher doses — so warn patients and families that tics may fluctuate on initiation or dose increases, without treating that possibility as a reason to withhold treatment altogether.^[7] If a genuine, bothersome tic exacerbation does occur, reducing the stimulant dose, adding an alpha-2 agonist, or switching to atomoxetine or an alpha-2 agonist alone are all reasonable next steps rather than abandoning ADHD treatment.^[7] Clonidine and guanfacine are also effective for ADHD symptoms (strong recommendation, moderate-quality evidence for both) though generally with a smaller effect size than stimulants, and are specifically unlikely to worsen tics — making them attractive first choices when both tics and ADHD need treatment simultaneously; the combination of methylphenidate plus clonidine has shown superior benefit to either agent alone for comorbid ADHD and tics.^[7] Atomoxetine (strong recommendation, moderate-quality evidence) is a reasonable non-stimulant alternative, with a smaller ADHD effect than stimulants but good evidence of tic non-inferiority to placebo.^[7] Health Canada and FDA product monographs for stimulants approved for ADHD continue, as of this guideline's underlying review, to carry cautionary language about use in patients with tics or a family history of TS — pharmacists should be aware this labelling has not caught up with the trial evidence and should not be the sole basis for withholding treatment.^[7]

• Education is itself a genuine, first-line intervention — for the majority of mild cases, giving the patient and family an accurate diagnosis and clear information about the natural course, prognosis, and treatment options is sufficient on its own, and this typically leads to a more conservative approach to medication, especially agents with a significant adverse-effect burden.^[2]
• CBIT/habit-reversal therapy (see Choose Initial Treatment) — the best-supported behavioural treatment, requiring active patient participation and tolerance of some distress, so it is not suitable for every patient, and is limited practically by the availability of trained therapists and cost/insurance coverage.^[4][1]
• School and workplace education — informing teachers and classmates about the nature of tics helps prevent unwarranted reprimands and teasing; a brief, 5-minute generic classroom presentation about tic disorders has been shown to significantly reduce bullying and improve the social experience of students with TS.^[1] Disciplining a child for having tics is not an effective strategy and should be actively discouraged.^[1]
• Protect the "release space" at home — explain the school-masking/home-"purging" pattern to parents explicitly, and encourage them to make home a place where a child does not need to suppress tics all evening.^[1]
• Individual psychotherapy or counseling can help patients who are especially sensitive to mild tics not easily noticed by others, and can help patients handle questions or comments about their tics from peers or the public.^[2]
• Address comorbid anxiety and sleep problems directly — both commonly amplify tic frequency and severity, and treating them can meaningfully reduce the perceived burden of tics without a tic-specific drug.
• Do not counsel patients to simply "suppress" or "stop" their tics through willpower alone as a management strategy — active voluntary suppression carries a real attentional/cognitive cost and builds a distressing urge; the older concern that deliberate suppression causes a later rebound worsening has, however, been more recently debunked, so structured suppression as taught in CBIT is not itself harmful.^[5][1]

Children versus adults

Most of the evidence in this chapter comes from pediatric studies, since TS is a childhood-onset disorder and most patients present in that period. Several agents (guanfacine, dextroamphetamine's tic data specifically, metoclopramide, ziprasidone) carry a formal recommendation only in children, with adult use graded Category X1 (insufficient trial evidence for a formal recommendation) and based instead on extrapolated clinical experience.^[4] Behavioural therapy (CBIT/HRT) is supported in both children and adults, though it is generally less effective in children aged 9 or younger, who often cannot yet reliably identify the premonitory urge the technique relies on.^[5]

Comorbid ADHD

See Choose Initial Treatment for the full discussion. In brief: appropriately dosed stimulants remain an effective, evidence-supported first-line ADHD treatment even in patients with tics, and should not be reflexively withheld; warn about possible tic fluctuation at initiation or dose changes without treating that possibility as disqualifying, and have a clear next step (dose reduction, add or switch to an alpha-2 agonist, or switch to atomoxetine) ready if genuine worsening occurs.^[7]

Comorbid OCD

Obsessive-compulsive symptoms in TS are managed using standard OCD treatment principles — an SSRI and/or exposure and response prevention — though tic-related OCD symptoms can have a distinct, more sensory or "just right" character than OCD without tics, and treatment response can differ accordingly; involve a clinician experienced with this specific overlap where possible.

Pregnancy and breastfeeding

Topiramate carries a specific, quantified risk first-trimester topiramate exposure is associated with an increased risk of oral clefts, with a dose-response relationship at doses above 100 mg/day — confirm reliable contraception before starting topiramate in a patient of reproductive potential, and discuss alternatives before a planned pregnancy. Antipsychotic and alpha-2 agonist use in pregnancy or breastfeeding should be discussed case by case with the prescriber, given limited condition-specific safety data for most of these agents; tetrabenazine is best avoided given its own limited pregnancy safety data.

Cardiac considerations

Pimozide and ziprasidone both carry a genuine QTc-prolongation risk obtain a baseline ECG before starting either, recheck with dose increases, and avoid combining them with other QT-prolonging drugs — including several of the other antipsychotics used for tics, so review the full medication list carefully before adding one of these agents on top of another.^[4]

Weight and metabolic risk

Avoid olanzapine, quetiapine, and risperidone in patients who are already overweight at baseline given the real risk of further weight gain and metabolic disturbance with these agents; aripiprazole is a comparatively (though not completely) weight-neutral alternative among the antipsychotics used for tics.^[4]

Renal and hepatic impairment

Topiramate is partially renally cleared and should be dose-reduced in significant renal impairment. Most antipsychotics used for tics are predominantly hepatically metabolized; use caution and consider dose reduction in significant hepatic impairment, and monitor more closely for accumulation of sedative and extrapyramidal effects.

Reassess tic severity and, just as importantly, functional impairment at every visit — ideally with a structured tool such as the YGTSS where available — rather than relying on visible tic frequency alone, since the goal of treatment is improved function, not the complete absence of tics.^[3]

Monitor blood pressure and heart rate through alpha-2 agonist titration and periodically thereafter; never stop clonidine abruptly given the risk of rebound hypertension.^[4] For antipsychotics, monitor weight, BMI, waist circumference, lipids, and glucose at baseline and periodically during treatment, along with a structured extrapyramidal symptom check; for pimozide and ziprasidone specifically, obtain a baseline ECG and recheck with dose changes.^[4] For tetrabenazine, monitor for new or worsening depression, anxiety, and parkinsonism, and reassess the ongoing risk-benefit balance closely given its very-low-quality evidence base and its described association with fatal pneumonia in case reports.^[4]

For stimulant or atomoxetine treatment of comorbid ADHD, specifically ask about tic frequency and severity at follow-up after starting or increasing the dose, but frame this as monitoring rather than an expectation of harm — most patients will not experience clinically meaningful worsening.^[7]

Because tic severity is expected to decline through adolescence into adulthood for most patients, periodically revisit whether ongoing medication is still needed, and consider a planned tapering trial rather than continuing indefinitely by default.^[4] Comorbidities can also evolve over the course of the disorder — for example, OCD symptoms sometimes become prominent only later — so comorbidity screening should be repeated at follow-up, not just at initial diagnosis.^[3]

1. Tics causing functional impairment not adequately controlled by CBIT/HRT alone: add pharmacotherapy per Choose Initial Treatment rather than continuing behavioural therapy alone indefinitely, particularly if impairment (school, social, physical injury) is ongoing.^[4]
2. Inadequate response to an adequate trial of one alpha-2 agonist: switch to the other alpha-2 agonist (clonidine to guanfacine, or vice versa) before moving to an antipsychotic, unless tic severity itself already warrants a stronger agent.
3. Inadequate response to alpha-2 agonist therapy, or more severe tics from the outset: move to risperidone or aripiprazole (second-line); if inadequate, move to pimozide, fluphenazine, or haloperidol (third-line), accepting a greater adverse-effect burden in exchange for the strongest efficacy evidence available.^[4]
4. Severely disabling focal motor tics or severe vocal tics/coprolalia refractory to oral pharmacotherapy: refer for botulinum toxin injection by an experienced clinician.^[4]
5. Genuinely refractory tics despite an adequate trial of behavioural therapy plus optimized first-, second-, and third-line pharmacotherapy: consider tetrabenazine, and in the most severe, medically refractory adult cases, refer for deep brain stimulation candidacy assessment through a specialized program — not in general practice.^[4][2]
6. Comorbid ADHD left undertreated specifically because of tic-worsening concerns: this is a common, correctable error — revisit and trial an appropriately dosed stimulant per the strong recommendation in Choose Initial Treatment, with a plan (dose adjustment, add/switch to an alpha-2 agonist, or switch to atomoxetine) ready if genuine tic worsening occurs, rather than leaving significant ADHD symptoms untreated indefinitely.^[7]
7. A presentation that looks like treatment-resistant TS but has an atypical, rapid-onset course, especially in an adolescent or young adult female: reconsider functional tic-like behaviour before assuming simple pharmacologic treatment failure, since the management approach differs.^[6]

• Treating "the tics" as the whole clinical picture while missing a far more functionally impairing, undertreated comorbid ADHD or OCD.^[3][1]
• Withholding an appropriately dosed stimulant for genuinely impairing ADHD out of the outdated, now evidence-updated concern that it will clearly worsen tics.^[7]
• Reaching for an antipsychotic before a genuine trial of behavioural therapy (CBIT/HRT) or an alpha-2 agonist for mild-moderate tics.^[4]
• Treating any detectable tic as automatically warranting medication, rather than assessing genuine functional, social, or physical impairment first.^[2]
• Starting pimozide or ziprasidone without a baseline ECG, or without checking for other QT-prolonging drugs already on the medication list.^[4]
• Punishing, reprimanding, or repeatedly telling a child to "just stop" their tics — an ineffective strategy that increases distress without reducing tics.^[1]
• Missing a rapid-onset, phenomenologically atypical tic-like presentation (especially in an adolescent or young adult female with no preceding childhood tic history) as straightforward Tourette syndrome, rather than considering functional tic-like behaviour.^[6]
• Telling families that medication will "cure" tics or change the underlying natural history, rather than explaining that it suppresses tics in the present while the expected improvement through adolescence proceeds on its own timeline.^[4]
• Continuing a tic medication indefinitely without periodically reassessing whether it is still needed, given the expected decline in tic severity through adolescence and early adulthood.^[4]
• Overlooking self-injurious tics (forceful neck/head "whiplash" tics, self-striking, eye-poking) as "just tics" rather than a specific indication for more active treatment.

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Alpha-2 Agonists — First-Line Pharmacotherapy for Tics

Preferred first pharmacologic step for mild-moderate tics given a more favourable adverse-effect profile than antipsychotics, with a genuine added benefit for comorbid ADHD symptoms. Titrate to blood pressure and heart rate; never stop abruptly.

Antipsychotics — Second- and Third-Line for More Severe or Refractory Tics

The oldest and most tic-specific class of medication, with the largest and highest-quality efficacy evidence of any tic treatment reviewed — the very reason clinicians historically reached for these first. They are placed second- or third-line here because of a genuine, significant extrapyramidal, sedative, and metabolic adverse-effect burden.

Other Pharmacotherapy for Tics

Reserve for patients in whom first- and second-line therapy is contraindicated, not tolerated, or inadequate, or for very specific severe/focal presentations.

ADHD Pharmacotherapy in Patients with Comorbid Tics

Short-term use of stimulants at moderate doses has not been found to worsen tics on average in randomized trial data, despite decades-old case-report-driven concern; do not withhold effective ADHD treatment for this reason alone. Monitor tics after starting or increasing the dose, and have a plan (dose adjustment, add/switch to an alpha-2 agonist, or switch to atomoxetine) ready if genuine worsening occurs.